- Neratinib in the context of an early breast cancer anti-HER2 therapy2020 | First Faculty of Medicine
- Neratinib in the adjuvant treatment of breast cancer - a case report2023 | Third Faculty of Medicine
- Research Report University Hospital for clinical assessment PUMA-NER-1301Publication without faculty affiliation
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial2017 | Publication without faculty affiliation
- New treatment options for HER2-dependent metastatic breast cancer2011 | First Faculty of Medicine
- Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients2021 | First Faculty of Medicine
- Pertuzumab in the neoadjuvant treatment of breast cancer2021 | First Faculty of Medicine